Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism

There are no approved drugs for the treatment of heart failure with preserved ejection fraction (HFpEF), which is characterized by left ventricular (LV) diastolic dysfunction. We demonstrate that ITF2357 (givinostat), a clinical-stage inhibitor of histone deacetylase (HDAC) catalytic activity, is ef...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Sci Transl Med
Prif Awduron: Jeong, Mark Y., Lin, Ying H., Wennersten, Sara A., Demos-Davies, Kimberly M., Cavasin, Maria A., Mahaffey, Jennifer H., Monzani, Valmen, Saripalli, Chandrasekhar, Mascagni, Paolo, Reece, T. Brett, Ambardekar, Amrut V., Granzier, Henk L., Dinarello, Charles A., McKinsey, Timothy A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908215/
https://ncbi.nlm.nih.gov/pubmed/29437146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aao0144
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg